SAN DIEGO, Oct. 13, 2017 /PRNewswire/ -- OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal fourth quarter and 2017 year-end financial results conference call on Wednesday, October 25th at 1:15 PM PT/4:15 PM ET.
To access the audio broadcast, please dial (877) 731- 1960 and enter the conference ID number: 86520374. An archived version of the presentation will be available for 90 days on the “Investors” section of OncoSec’s website: http://ir.oncosec.com/events-presentations.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or “tavo”). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-to-host-fourth-quarter-and-year-end-financial-results-conference-call-on-october-25-2017-300536263.html
SOURCE OncoSec Medical Incorporated
